Is RNXT or HSCS more profitable?

HeartSciences has a net margin of 0.00% compared to RenovoRx's net margin of -621.71%. RenovoRx's return on equity of -135.11% beat HeartSciences' return on equity. Company Net Margins Return on Equity Return on Assets RenovoRx -621.71% -135.11% -101.91% HeartSciences N/A -816.90% -181.97%

Does the media refer more to RNXT or HSCS?

In the previous week, RenovoRx and RenovoRx both had 5 articles in the media. HeartSciences' average media sentiment score of 0.83 beat RenovoRx's score of -0.17 indicating that HeartSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RenovoRx 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral HeartSciences 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CVRX or HSCS more profitable?

HeartSciences has a net margin of 0.00% compared to CVRx's net margin of -84.93%. CVRx's return on equity of -152.35% beat HeartSciences' return on equity. Company Net Margins Return on Equity Return on Assets CVRx -84.93% -152.35% -50.93% HeartSciences N/A -816.90% -181.97%

Does the media refer more to CVRX or HSCS?

In the previous week, HeartSciences had 3 more articles in the media than CVRx. MarketBeat recorded 5 mentions for HeartSciences and 2 mentions for CVRx. HeartSciences' average media sentiment score of 0.83 beat CVRx's score of 0.65 indicating that HeartSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CVRx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive HeartSciences 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend HSCS or DXR?

HeartSciences currently has a consensus target price of $8.00, indicating a potential upside of 151.57%. Given HeartSciences' higher probable upside, research analysts plainly believe HeartSciences is more favorable than Daxor. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HeartSciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Daxor 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has better earnings & valuation, HSCS or DXR?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio HeartSciences N/A N/A -$9.14M -$3.22 N/A Daxor N/A N/A N/A N/A N/A

Is HSCS or DXR more profitable?

Daxor's return on equity of 0.00% beat HeartSciences' return on equity. Company Net Margins Return on Equity Return on Assets HeartSciences N/A -816.90% -181.97% Daxor N/A N/A N/A

Does the media favor HSCS or DXR?

In the previous week, HeartSciences had 2 more articles in the media than Daxor. MarketBeat recorded 5 mentions for HeartSciences and 3 mentions for Daxor. HeartSciences' average media sentiment score of 0.83 beat Daxor's score of 0.27 indicating that HeartSciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HeartSciences 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Daxor 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer HSAQ or HSCS?

HeartSciences has a consensus price target of $8.00, suggesting a potential upside of 151.57%. Given HeartSciences' stronger consensus rating and higher possible upside, analysts plainly believe HeartSciences is more favorable than Health Sciences Acquisitions Co. 2. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Health Sciences Acquisitions Co. 2 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 HeartSciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings and valuation, HSAQ or HSCS?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Health Sciences Acquisitions Co. 2 N/A N/A -$380K N/A N/A HeartSciences N/A N/A -$9.14M -$3.22 N/A

Is HSAQ or HSCS more profitable?

Health Sciences Acquisitions Co. 2's return on equity of 0.00% beat HeartSciences' return on equity. Company Net Margins Return on Equity Return on Assets Health Sciences Acquisitions Co. 2 N/A N/A -2.38% HeartSciences N/A -816.90% -181.97%

HeartSciences (HSCS) Competitors

$3.29 +0.11 (+3.58%)

As of 12:15 PM Eastern

Compare

HSCS vs. RNXT, CVRX, DXR, HSAQ, and OM

Should you buy HeartSciences stock or one of its competitors? HeartSciences's main competitors and comparable companies include RenovoRx (RNXT), CVRx (CVRX), Daxor (DXR), Health Sciences Acquisitions Co. 2 (HSAQ), and Outset Medical (OM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does HeartSciences compare to RenovoRx?

RenovoRx (NASDAQ:RNXT) and HeartSciences (NASDAQ:HSCS) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, valuation, dividends and profitability.

3.1% of RenovoRx shares are held by institutional investors. Comparatively, 17.2% of HeartSciences shares are held by institutional investors. 9.4% of RenovoRx shares are held by company insiders. Comparatively, 4.9% of HeartSciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, RenovoRx and RenovoRx both had 5 articles in the media. HeartSciences' average media sentiment score of 0.83 beat RenovoRx's score of -0.17 indicating that HeartSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RenovoRx	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral
HeartSciences	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

HeartSciences has lower revenue, but higher earnings than RenovoRx. RenovoRx is trading at a lower price-to-earnings ratio than HeartSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RenovoRx	$1.12M	51.58	-$11.17M	-$0.31	N/A
HeartSciences	N/A	N/A	-$9.14M	-$3.22	N/A

HeartSciences has a net margin of 0.00% compared to RenovoRx's net margin of -621.71%. RenovoRx's return on equity of -135.11% beat HeartSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RenovoRx	-621.71%	-135.11%	-101.91%
HeartSciences	N/A	-816.90%	-181.97%

RenovoRx currently has a consensus price target of $8.50, suggesting a potential upside of 564.06%. HeartSciences has a consensus price target of $8.00, suggesting a potential upside of 151.57%. Given RenovoRx's stronger consensus rating and higher possible upside, equities research analysts plainly believe RenovoRx is more favorable than HeartSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RenovoRx	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
HeartSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

RenovoRx has a beta of 0.98, suggesting that its stock price is 2% less volatile than the broader market. Comparatively, HeartSciences has a beta of 1.76, suggesting that its stock price is 76% more volatile than the broader market.

Summary

RenovoRx beats HeartSciences on 9 of the 15 factors compared between the two stocks.

How does HeartSciences compare to CVRx?

CVRx (NASDAQ:CVRX) and HeartSciences (NASDAQ:HSCS) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, institutional ownership, media sentiment, risk, dividends, analyst recommendations, profitability and earnings.

CVRx has a beta of 0.77, meaning that its stock price is 23% less volatile than the broader market. Comparatively, HeartSciences has a beta of 1.76, meaning that its stock price is 76% more volatile than the broader market.

In the previous week, HeartSciences had 3 more articles in the media than CVRx. MarketBeat recorded 5 mentions for HeartSciences and 2 mentions for CVRx. HeartSciences' average media sentiment score of 0.83 beat CVRx's score of 0.65 indicating that HeartSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CVRx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
HeartSciences	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CVRx presently has a consensus target price of $4.30, suggesting a potential upside of 172.15%. HeartSciences has a consensus target price of $8.00, suggesting a potential upside of 151.57%. Given CVRx's stronger consensus rating and higher possible upside, research analysts plainly believe CVRx is more favorable than HeartSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CVRx	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17
HeartSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

HeartSciences has a net margin of 0.00% compared to CVRx's net margin of -84.93%. CVRx's return on equity of -152.35% beat HeartSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CVRx	-84.93%	-152.35%	-50.93%
HeartSciences	N/A	-816.90%	-181.97%

75.3% of CVRx shares are held by institutional investors. Comparatively, 17.2% of HeartSciences shares are held by institutional investors. 16.6% of CVRx shares are held by company insiders. Comparatively, 4.9% of HeartSciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

HeartSciences has lower revenue, but higher earnings than CVRx. HeartSciences is trading at a lower price-to-earnings ratio than CVRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CVRx	$56.65M	0.74	-$53.31M	-$1.98	N/A
HeartSciences	N/A	N/A	-$9.14M	-$3.22	N/A

Summary

CVRx beats HeartSciences on 10 of the 15 factors compared between the two stocks.

How does HeartSciences compare to Daxor?

HeartSciences (NASDAQ:HSCS) and Daxor (NASDAQ:DXR) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

17.2% of HeartSciences shares are held by institutional investors. Comparatively, 1.3% of Daxor shares are held by institutional investors. 4.9% of HeartSciences shares are held by company insiders. Comparatively, 51.5% of Daxor shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Daxor's return on equity of 0.00% beat HeartSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HeartSciences	N/A	-816.90%	-181.97%
Daxor	N/A	N/A	N/A

HeartSciences has a beta of 1.76, meaning that its share price is 76% more volatile than the broader market. Comparatively, Daxor has a beta of 0.35, meaning that its share price is 65% less volatile than the broader market.

In the previous week, HeartSciences had 2 more articles in the media than Daxor. MarketBeat recorded 5 mentions for HeartSciences and 3 mentions for Daxor. HeartSciences' average media sentiment score of 0.83 beat Daxor's score of 0.27 indicating that HeartSciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HeartSciences	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Daxor	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HeartSciences	N/A	N/A	-$9.14M	-$3.22	N/A
Daxor	N/A	N/A	N/A	N/A	N/A

HeartSciences currently has a consensus target price of $8.00, indicating a potential upside of 151.57%. Given HeartSciences' higher probable upside, research analysts plainly believe HeartSciences is more favorable than Daxor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HeartSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Daxor	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

HeartSciences beats Daxor on 5 of the 9 factors compared between the two stocks.

How does HeartSciences compare to Health Sciences Acquisitions Co. 2?

Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) and HeartSciences (NASDAQ:HSCS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations.

Health Sciences Acquisitions Co. 2's return on equity of 0.00% beat HeartSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Health Sciences Acquisitions Co. 2	N/A	N/A	-2.38%
HeartSciences	N/A	-816.90%	-181.97%

HeartSciences has a consensus price target of $8.00, suggesting a potential upside of 151.57%. Given HeartSciences' stronger consensus rating and higher possible upside, analysts plainly believe HeartSciences is more favorable than Health Sciences Acquisitions Co. 2.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Health Sciences Acquisitions Co. 2	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
HeartSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

89.7% of Health Sciences Acquisitions Co. 2 shares are owned by institutional investors. Comparatively, 17.2% of HeartSciences shares are owned by institutional investors. 21.9% of Health Sciences Acquisitions Co. 2 shares are owned by insiders. Comparatively, 4.9% of HeartSciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, HeartSciences had 5 more articles in the media than Health Sciences Acquisitions Co. 2. MarketBeat recorded 5 mentions for HeartSciences and 0 mentions for Health Sciences Acquisitions Co. 2. HeartSciences' average media sentiment score of 0.83 beat Health Sciences Acquisitions Co. 2's score of 0.00 indicating that HeartSciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Health Sciences Acquisitions Co. 2	Neutral
HeartSciences	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Health Sciences Acquisitions Co. 2	N/A	N/A	-$380K	N/A	N/A
HeartSciences	N/A	N/A	-$9.14M	-$3.22	N/A

Health Sciences Acquisitions Co. 2 has a beta of 0.09, meaning that its share price is 91% less volatile than the broader market. Comparatively, HeartSciences has a beta of 1.76, meaning that its share price is 76% more volatile than the broader market.

Summary

HeartSciences beats Health Sciences Acquisitions Co. 2 on 6 of the 11 factors compared between the two stocks.

How does HeartSciences compare to Outset Medical?

HeartSciences (NASDAQ:HSCS) and Outset Medical (NASDAQ:OM) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation and profitability.

17.2% of HeartSciences shares are held by institutional investors. 4.9% of HeartSciences shares are held by insiders. Comparatively, 2.5% of Outset Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, HeartSciences had 4 more articles in the media than Outset Medical. MarketBeat recorded 5 mentions for HeartSciences and 1 mentions for Outset Medical. Outset Medical's average media sentiment score of 1.79 beat HeartSciences' score of 0.83 indicating that Outset Medical is being referred to more favorably in the news media.

Company	Overall Sentiment
HeartSciences	Positive
Outset Medical	Very Positive

HeartSciences has higher earnings, but lower revenue than Outset Medical. Outset Medical is trading at a lower price-to-earnings ratio than HeartSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HeartSciences	N/A	N/A	-$9.14M	-$3.22	N/A
Outset Medical	$119.48M	0.64	-$81.65M	-$4.09	N/A

HeartSciences currently has a consensus price target of $8.00, suggesting a potential upside of 151.57%. Outset Medical has a consensus price target of $10.00, suggesting a potential upside of 146.91%. Given HeartSciences' higher possible upside, analysts plainly believe HeartSciences is more favorable than Outset Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HeartSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Outset Medical	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

HeartSciences has a net margin of 0.00% compared to Outset Medical's net margin of -63.06%. Outset Medical's return on equity of -61.67% beat HeartSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HeartSciences	N/A	-816.90%	-181.97%
Outset Medical	-63.06%	-61.67%	-28.25%

HeartSciences has a beta of 1.76, meaning that its stock price is 76% more volatile than the broader market. Comparatively, Outset Medical has a beta of 1.99, meaning that its stock price is 99% more volatile than the broader market.

Summary

HeartSciences beats Outset Medical on 8 of the 15 factors compared between the two stocks.

Get HeartSciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HSCS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HSCS vs. The Competition

Export

Metric	HeartSciences	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$15.94M	$5.54B	$7.25B	$13.25B
Dividend Yield	N/A	1.77%	2.53%	22.58%
P/E Ratio	-1.02	25.73	275.71	25.92
Price / Sales	N/A	70.26	580.08	79.95
Price / Cash	N/A	32.56	27.30	36.12
Price / Book	47.06	5.99	10.89	6.12
Net Income	-$9.14M	$146.14M	$3.50B	$380.72M
7 Day Performance	-24.45%	-0.73%	-1.62%	-1.94%
1 Month Performance	-2.83%	-2.21%	-4.42%	-3.89%
1 Year Performance	-5.62%	4.38%	6.47%	0.91%

HeartSciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HSCS HeartSciences	3.2351 of 5 stars	$3.29 +3.6%	$8.00 +142.9%	-8.9%	$15.94M	N/A	N/A	14
RNXT RenovoRx	2.2042 of 5 stars	$1.56 -0.6%	$8.50 +444.9%	+15.3%	$70.85M	$1.12M	N/A	17
CVRX CVRx	3.6722 of 5 stars	$1.75 -33.5%	$4.30 +145.7%	-82.3%	$70.07M	$56.65M	N/A	223	Analyst Upgrade High Trading Volume
DXR Daxor	1.3974 of 5 stars	$11.25 -3.8%	N/A	-17.4%	$68.31M	N/A	N/A	37	News Coverage Short Interest Increase
HSAQ Health Sciences Acquisitions Co. 2	N/A	$6.08 +3.2%	N/A	+88.9%	$68.17M	N/A	N/A	4

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HSCS) was last updated on 10/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

HeartSciences (HSCS) Competitors

HSCS vs. RNXT, CVRX, DXR, HSAQ, and OM

How does HeartSciences compare to RenovoRx?

Summary

How does HeartSciences compare to CVRx?

Summary

How does HeartSciences compare to Daxor?

Summary

How does HeartSciences compare to Health Sciences Acquisitions Co. 2?

Summary

How does HeartSciences compare to Outset Medical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HSCS vs. The Competition

HeartSciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

HeartSciences (HSCS) Competitors

HSCS vs. RNXT, CVRX, DXR, HSAQ, and OM

How does HeartSciences compare to RenovoRx?

Do insiders & institutionals hold more shares of RNXT or HSCS?

Does the media refer more to RNXT or HSCS?

Which has higher valuation and earnings, RNXT or HSCS?

Is RNXT or HSCS more profitable?

Do analysts rate RNXT or HSCS?

Which has more volatility and risk, RNXT or HSCS?

Summary

How does HeartSciences compare to CVRx?

Which has more volatility & risk, CVRX or HSCS?

Does the media refer more to CVRX or HSCS?

Do analysts prefer CVRX or HSCS?

Is CVRX or HSCS more profitable?

Do institutionals and insiders hold more shares of CVRX or HSCS?

Which has better earnings & valuation, CVRX or HSCS?

Summary

How does HeartSciences compare to Daxor?

Do insiders and institutionals have more ownership in HSCS or DXR?

Is HSCS or DXR more profitable?

Which has more volatility and risk, HSCS or DXR?

Does the media favor HSCS or DXR?

Which has better earnings & valuation, HSCS or DXR?

Do analysts recommend HSCS or DXR?

Summary

How does HeartSciences compare to Health Sciences Acquisitions Co. 2?

Is HSAQ or HSCS more profitable?

Do analysts prefer HSAQ or HSCS?

Do insiders & institutionals hold more shares of HSAQ or HSCS?

Does the media refer more to HSAQ or HSCS?

Which has better earnings and valuation, HSAQ or HSCS?

Which has more risk & volatility, HSAQ or HSCS?

Summary

How does HeartSciences compare to Outset Medical?

Do institutionals & insiders believe in HSCS or OM?

Does the media prefer HSCS or OM?

Which has stronger valuation and earnings, HSCS or OM?

Do analysts rate HSCS or OM?

Is HSCS or OM more profitable?

Which has more volatility & risk, HSCS or OM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HSCS vs. The Competition

HeartSciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools